Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Statins at the Primary Care Level (EPRINA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02380911
Recruitment Status : Completed
First Posted : March 5, 2015
Last Update Posted : August 16, 2017
Sponsor:
Information provided by (Responsible Party):
Institute for Clinical Effectiveness and Health Policy

Brief Summary:
Hypercholesterolemia, a major cause of disease burden in both the developed and developing world, is estimated to cause 2.6 million deaths annually (4.5% of all deaths) and one third of ischemic heart diseases., and result in 29.7 million DALY lost. In Argentina, the prevalence of hypercholesterolemia increased between 2005 and 2013 from 27.9% to 29.8%, whereas the rate of non-optimal LDL-C, was 28.0%. The rate of high cholesterol awareness was 37.3 % and the proportion of those who are under pharmacological treatment was dismally low: only 11.1%. Furthermore, only one out of four subjects with a self-reported diagnosis of coronary heart disease (CHD) is taking statins. and most individuals with CHD who are on statins have sub-optimal LDL-C levels. Although other antihypertensive, antidiabetic and low-dose aspirin were available free-of-charge at the primary care clinics of the public sector, statins had not been included until recently. As of 2014, statins (simvastatin 20mg) were incorporated into the package of drugs provided free-of-charge for patients with high cholesterol, according to CVD risk stratification. The goal of this study is to test whether a multifaceted educational intervention targeting physicians and pharmacist assistants, improves detection, treatment and control of hypercholesterolemia among uninsured patients with moderate to high cardiovascular risk in Argentina. Specifically, the intervention will test whether a multifaceted educational intervention program lowers LDL-cholesterol levels and CVD risk in moderate to high cardiovascular risk patients, improves physician compliance with clinical practice guidelines, and improves patient care management and adherence to medication. A cost-effectiveness study will be conducted to compare the intervention to the usual standard of care. This randomized cluster trial will enroll 350 patients from 10 public primary care clinics who will be assigned to receive either the intervention or the usual care. This study is timely and will generate urgently needed data on effective and, practical and sustainable intervention programs aimed at the prevention and control of CVD risk that can be directly used in other primary care settings and health care systems in LMICs.

Condition or disease Intervention/treatment Phase
Dyslipidemia Other: Educational Intervention Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 357 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Other
Official Title: An Educational Intervention to Improve Effectiveness in the Detection, Treatment and Control of Patients With High Cardiovascular Risk in Low-resource Settings in Argentina: Rationale and Study Design of a Cluster Randomized Controlled Trial.
Study Start Date : April 2015
Actual Primary Completion Date : April 2017
Actual Study Completion Date : April 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Intervention Group
The intervention group will receive a multifaceted educational intervention targeting physicians and pharmacist assistants to improve detection, treatment and control of hypercholesterolemia among uninsured patients with moderate-high cardiovascular risk in Argentina.
Other: Educational Intervention

Physicians belonging to the PCC randomized to the intervention group receive a 3-component intervention: education workshop, Educational Outreach Visits and a mHealth application uploaded to their smartphones.

In addition, 2 intervention support tools are used at the intervention clinics:

  1. A web-based platform that is tailored to send SMS messages for lifestyle modification, and prompts and reminders for clinic appointments are used to improve medication adherence for patients.
  2. On-site training to pharmacist assistants at the first EOV is given by physician trainers focused on counseling to improve medication adherence among patients initiating statin therapy and at each patient visit to the clinic to refill drug prescriptions.

No Intervention: No Intervention Group
This group will continue with the usual care. Irrespective of the assignment of the clinic to the intervention or control group, all physicians from participating PCCs have received previous training on global cardiovascular risk management, given by the Ministry of Health



Primary Outcome Measures :
  1. Cholesterol Level [ Time Frame: 1 year ]
    Net change in LDL-C levels from baseline to month 12 between intervention and usual care groups among all study participants.


Secondary Outcome Measures :
  1. Global Cardiovascular Risk [ Time Frame: 1 year ]
    Net change in 10-year-CVD Framingham risk score before and after the implementation of the program.

  2. Clinical practice guidelines compliance [ Time Frame: 1 year ]
    Proportion of patients with high CVD risk who are on statins, and are receiving an appropriate dose according to the CPG.

  3. Cholesterol reduction [ Time Frame: 1 year ]
    Proportion of patients with moderate-high CVD risk who have reduced 30% and 50% of their LDL-C, respectively.

  4. Treatment compliance [ Time Frame: 1 year ]
    Level of treatment adherence evaluated through questionnaire.

  5. Costs of the intervention [ Time Frame: 1 year ]
    Cost-effectiveness of the intervention program.


Other Outcome Measures:
  1. Cholesterol Level stratified by history of diabetes [ Time Frame: 1 year ]
    Net change in LDL-C levels from baseline to month 12 between intervention and usual care groups stratified by history of diabetes.

  2. Global Cardiovascular Risk stratified by history of diabetes [ Time Frame: 1 year ]
    Net change in 10-year-CVD Framingham risk score before and after the implementation of the program stratified by history of diabetes.

  3. Clinical practice guidelines compliance stratified by history of diabetes [ Time Frame: 1 year ]
  4. Cholesterol reduction stratified by history of diabetes [ Time Frame: 1 year ]
  5. Treatment compliance stratified by history of diabetes [ Time Frame: 1 year ]
  6. Cholesterol level stratified by 10-year-CVD Framingham risk score level. [ Time Frame: 1 year ]
  7. Clinical practice guidelines compliance stratified by 10-year-CVD Framingham risk score level. [ Time Frame: 1 year ]
  8. Cholesterol reduction stratified by 10-year-CVD Framingham risk score level. [ Time Frame: 1 year ]
  9. Treatment compliance stratified by stratified by 10-year-CVD Framingham risk score level. [ Time Frame: 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Arteriosclerotic cardiovascular disease: defined as acute coronary syndrome; history of myocardial infarction, stable or unstable angina, coronary revascularization, stroke, or transient ischemic attack presumed to be of atherosclerotic origin and revascularization.
  • Moderate-High CVD risk according to the WHO charts adapted by the National MoH (estimated 10-year CVD risk ≥ 20%)
  • LDL-C level ≥ 190 mg/dL
  • Type 2 diabetes in patients between 40 and 75 years of age

Exclusion Criteria:

  • Patients that are already receiving statins, pregnant women, bed-bound, and patients who cannot give informed consent.
  • End stage chronics kidney disease receiving dialysis ,HIV/AIDS, tuberculosis, alcohol or drugs abuse.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02380911


Locations
Layout table for location information
Argentina
Centro de Atención Primaria de la Salud "Dr. Favaloro"
Puerto Madryn, Chubut, Argentina
Centro de Atención Primaria de la Salud "Ruca Calil"
Puerto Madryn, Chubut, Argentina
Centro de Atención Primaria de la Salud "Malvinas Argentinas"
Rawson, Chubut, Argentina
Centro de Atención Primaria de la Salud "Etcheparre"
Trelew, Chubut, Argentina
Hospital San Luis del Palmar
San Luis del Palmar, Corrientes, Argentina
Centro de Atención Primaria de la Salud N°11
Corrientes, Argentina, 1034
Centro de Atención Primaria de la Salud Dr. Balbastro
Corrientes, Argentina
Centro de Atención Primaria de la Salud N°13
Corrientes, Argentina
Centro de Atención Primaria "Jardín Residencial"
La Rioja, Argentina
Centro de Atención Primaria de la Salud "Faldeo del Velazco"
La Rioja, Argentina
Sponsors and Collaborators
Institute for Clinical Effectiveness and Health Policy
Investigators
Layout table for investigator information
Principal Investigator: Adolfo Rubinstein, MD, MSc, PhD Institute for Clinical Effectiveness and Health Policy

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Institute for Clinical Effectiveness and Health Policy
ClinicalTrials.gov Identifier: NCT02380911     History of Changes
Other Study ID Numbers: 11526941
First Posted: March 5, 2015    Key Record Dates
Last Update Posted: August 16, 2017
Last Verified: August 2017

Keywords provided by Institute for Clinical Effectiveness and Health Policy:
Dyslipidemia
Global cardiovascular risk
Statins
Educational interventions

Additional relevant MeSH terms:
Layout table for MeSH terms
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases